drugset

drugset / Trial / NCT00206427

Neoadjuvant GW572016 to Treat Breast Cancer

NCT00206427 ↗

Phase 2 Completed 49 enrolled Baylor Breast Care Center GlaxoSmithKline · collab

NaSingle-groupOpen-labelTreatment

Summary

We want to learn whether GW572016 is effective in breast cancers that have HER2.

Timeline

Start: 2004-08
Primary completion: 2011-06
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapatinib	Small molecule	500 mg	Oral

Indications